The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system.
about
Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationModulation of therapeutic sensitivity by human papillomavirusViruses and human cancers: a long road of discovery of molecular paradigms.hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Characterization of HPV and host genome interactions in primary head and neck cancers.ONCOGENIC HUMAN PAPILLOMAVIRUSES: High-Risk Human Papillomaviruses: Towards a Better Understanding of the Mechanisms of Viral Transformation, Latency and Immune-Escape[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapyCUL2 overexpression driven by CUL2/E2F1/miR-424 regulatory loop promotes HPV16 E7 induced cervical carcinogenesis.Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases.Human papillomavirus: current status and issues of vaccination.Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers.Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing.Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment - a retrospective analysis.Telomerase Induction in HPV Infection and Oncogenesis.ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.Implication of HLA-G 3' untranslated region polymorphisms in human papillomavirus infection.How Human Papillomavirus Replication and Immune Evasion Strategies Take Advantage of the Host DNA Damage Repair Machinery.Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.Therapeutic cancer vaccines.A Targeted LC-MS Strategy for Low-Abundant HLA Class-I-Presented Peptide Detection Identifies Novel Human Papillomavirus T-Cell Epitopes.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.
P2860
Q26765060-B4FFBA4E-CA1E-4ED3-A0C6-F3F98FE2202AQ28087031-D6BDA9B5-0417-4947-974B-ED02ABE289E5Q30384388-033DB910-4DAB-4A0F-99D4-35BAAC346A76Q33730462-A5E4AB20-CCCD-4959-8FF9-E8C5BEA5F035Q33908553-69BD3264-F996-4BEA-8324-45FFDE698D89Q34442327-8A36FDF7-B91D-47D6-ACFA-BD93FD83904AQ36554397-49044EEA-CE4A-428D-A2A0-E19265F7D253Q36691460-805DFA22-3D6D-4287-89F7-F05792E03DEDQ37327810-C83E8B20-A6FF-447C-BB02-BF25B0383418Q37414728-4FB3C88B-CAB0-4F47-8421-22EA7AE3FE09Q38136127-F117C6D1-28F5-4C41-99A1-4AB82117ED69Q38209942-DB3A3F80-FFC4-4984-9D23-C540FA158FAEQ38467933-A01CFD18-D221-4090-9ECF-3274920EB34FQ38592522-67D4F4C4-B393-4C4B-AEEC-D87A59E652F0Q39429557-00A37342-3BB8-4349-B057-3791C986F115Q40091834-780C1442-7013-426D-B99E-97E2735C743BQ42218961-66F9F2C3-272D-407F-A7FE-0FC4BF7F540FQ42244757-73E6CA13-2481-497F-AFC7-58193FCC4530Q47159047-DC6D35ED-97C8-4E40-BE86-8F66EF6958D2Q47558629-61BD7F04-E1E0-41AA-AABA-4EAE297487D0Q50988785-58FA9CE2-9A3E-4FEA-AFD0-DD2B8686D5C9Q52617409-3643B230-A163-4C6A-99B3-505EF337154AQ54215275-A325FE9F-6265-4155-AC36-1EA5DD19470AQ54965346-E1CCB3C6-48D0-455A-86BF-321DFFD0D02BQ55003290-B8F4A0A4-BC24-4B85-B547-07980A15B962
P2860
The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The invisible enemy - how huma ...... nce by the host immune system.
@ast
The invisible enemy - how huma ...... nce by the host immune system.
@en
type
label
The invisible enemy - how huma ...... nce by the host immune system.
@ast
The invisible enemy - how huma ...... nce by the host immune system.
@en
prefLabel
The invisible enemy - how huma ...... nce by the host immune system.
@ast
The invisible enemy - how huma ...... nce by the host immune system.
@en
P2860
P1476
The invisible enemy - how huma ...... nce by the host immune system.
@en
P2093
Agnieszka K Grabowska
P2860
P304
P356
10.2174/1874357901206010249
P577
2012-12-28T00:00:00Z